AMKAY.BO · BSE
Amkay Products Limited
₹63.98
+10.31% (+₹5.98)
Prev. close
₹58
Volume
18,000
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Amkay Products Limited
Amkay Products Limited manufactures, assembles, and markets a portfolio of medical devices, disposables, and other healthcare products in India. The company offers face masks, alcohol swabs, lancet needles, nebulizers, pulse oximeters, surgeon caps, blood pressure monitors, air bed, adult diapers, hot water bags, HIV kits, bio bags, suction machines, apron gowns, gluco strips, thermometer, vaporizer, ambu bag, fetal dropper, body massager, breast pump, stature meter, bed bath towel, show cover, bed sheet, gloves, lancing pen, prep razor/skin blade, cord clamp, and torniquet, as well as urine pad and bag. It serves medical professionals, retailers, hospitals, prestigious institutes, government bodies, pharmaceutical companies, distributors, and dealers. The company also exports its products to Bhutan, Nepal, and internationally. Amkay Products Limited was incorporated in 2007 and is headquartered in Palghar, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Kashyap Pravin Mody
Headquarters
Palghar
Employees
123
Website
amkayproducts.comExchange
View on BSE ↗Key stats
Market cap
₹53.45 Cr
P/E ratio (TTM)
23.1
EPS (TTM)
₹2.67
Beta (1Y · daily vs NIFTY 50)
0.33
Shares float
21.82 L
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide. Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹27.86 Cr | ₹31.07 Cr | ₹38.39 Cr | ₹42.03 Cr | |
| EBITDA | — | ₹3.51 Cr | ₹4.58 Cr | ₹5.44 Cr | ₹4.52 Cr |
| — | ₹1.51 Cr | ₹2.63 Cr | ₹3.34 Cr | ₹2.31 Cr | |
| Diluted EPS | ₹1.69 | ₹1.74 | ₹3.04 | ₹3.96 | — |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹15.81 Cr | ₹15.64 Cr | — | ₹29.89 Cr | ₹33.31 Cr | |
| ₹4.34 Cr | ₹4.70 Cr | — | ₹2.64 Cr | ₹3.93 Cr | |
| Stockholders' equity | ₹6.21 Cr | ₹7.72 Cr | — | ₹24.07 Cr | ₹26.38 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹97.71 L | ₹-66.03 L | ₹-31.48 L | ₹1.18 Cr | |
| Investing cash flow | — | ₹-1.39 Cr | ₹47.89 L | ₹-5.84 Cr | ₹-39.73 L |
| — | ₹25.61 L | ₹23.96 L | ₹7.58 Cr | ₹85.59 L | |
| Capital expenditure | — | ₹-2.34 L | ₹-73.01 L | ₹-2.48 Cr | ₹-89.73 L |
| End cash position | — | ₹4.99 L | ₹10.81 L | ₹1.54 Cr | ₹3.18 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Amkay Products Limited | ₹53.45 Cr | ₹58 | 23.1 | 2.03 | 8.8% | 0.15 | +9.5% | +18.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.